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Abstract
Background: Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by renal phosphate
wasting, hypophosphatemia, reduction of 1,25-dihydroxyl vitamin D, and bone calcification disorders. Tumors
associated with TIO are typically phosphaturic mesenchymal tumors that are bone and soft tissue origin and
often present as a solitary tumor. The high production of fibroblast growth factor 23 (FGF23) by the tumor is
believed to be the causative factor responsible for the impaired renal tubular phosphate reabsorption, hypophosphatemia
and osteomalacia. Complete removal of the tumors by surgery is the most effective procedure for treatment.
Identification of the tumors by advanced imaging techniques is difficult because TIO is small and exist within bone and
soft tissue. However, systemic venous sampling has been frequently reported to be useful for diagnosing TIO patients.
Case presentation: We experienced a case of 39-year-old male with diffuse bone pain and multiple fragility
fractures caused by multiple FGF23-secreting tumors found in the hallux. Laboratory testing showed hypophosphatemia
due to renal phosphate wasting and high levels of serum FGF23. Contrast-enhanced MRI showed three soft tissue tumors
and an intraosseous tumor located in the right hallux. Systemic venous sampling of FGF23 revealed an elevation in the
right common iliac vein and external iliac vein, which suggested that the tumors in the right hallux were responsible for
overproduction of FGF23. Thereafter, these tumors were surgically removed and subjected to histopathological
examinations. The three soft tissue tumors were diagnosed as phosphaturic mesenchymal tumors, which are
known to be responsible for TIO. The fourth tumor had no tumor structure and was consisting of hyaline cartilage and
bone tissue. Immediately after surgery, we noted a sharply decrease in serum level of FGF23, associated with
an improved hypophosphatemia and a gradual relief of systematic pain that disappeared within two months
of surgery.
Conclusion: The authors reported an unusual case of osteomalacia induced by multiple phosphaturic mesenchymal
tumors located in the hallux. Definition of tumors localization by systemic venous sampling led to successful treatment
and cure this patient. The presence of osteochondral tissues in the intraosseous tumor might be developed
from undifferentiated mesenchymal cells due to high level of FGF23 produced by phosphaturic mesenchymal
tumors.
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Background
Tumor-induced osteomalacia (TIO) is a rare paraneo-
plastic syndrome characterized by overproduction of
fibroblast growth factor 23 (FGF23), defect in vitamin
D metabolism, chronic hypophosphatemia, and dis-
order in bone calcification. Phosphaturic mesenchymal
tumors associated with osteomalacia produce high
FGF23, which inhibits phosphate transport in renal
proximal tubule epithelial cells, resulting in renal
phosphate wasting [1–3]. Moreover, FGF23 reduces
circulating 1,25-dihydroxyl vitamin D through sup-
pressing the production of 1-alpha hydroxylase. The
deficiency of the circulating levels of phosphorus and
1,25-dihydroxyl vitamin D impairs mineralization of
osteoid matrix in mature bone leading to a defect in
the bone-building process.
Muscle weakness, myalgia and bone pain are the major
clinical symptoms of TIO, and patients are commonly
misdiagnosed with other illnesses such as rheumatologic
diseases or psychiatric disorders [4, 5]. Patients with
advanced osteomalacia may suffer from fragility fracture
and gait disturbance due to the impairment in bone
quality. Multiple fragility fractures are often occurred in
ribs, vertebral bodies, and femoral neck [6, 7]. Complete
surgical resection of the tumors cures TIO dramatically
improves the metabolism of phosphorus and restores
the normal levels of circuiting vitamin D, resulting in
rapid resolution of clinical symptoms within a few
weeks. However, diagnosis of TIO is always challenging
and is delayed in most cases due to the small size and
slow growth of these tumors. High-resolution magnetic
resonance imaging (MRI) and F-18 fluorodeoxyglucose
positron emission tomography (FDGF-PET) are pro-
posed to be beneficial modalities to define the location
of the tumor. Moreover, DOTATOC-PET/CT has been
reported to be a feasible option for localizing causative
tumors in patients with TIO [8], but this modality is not
approved in our county. Systemic venous sampling that
detects the excess production of FGF23 in the culprit
tumor has recently emerged as greater technique for
precise definition of tumor location [9, 10].
Phosphaturic mesenchymal tumors associated with
TIO are polymorphous neoplasms that are originated
from bone or soft tissue. These tumors are typically not
malignant composing of spindled-stellate cells that ap-
pears normochromatic, small with indistinct nucleoli. In
the most of published cases, nuclear atypia and mitotic
activity are low [11–13]. Generally, they are nonaggres-
sive tumors and appear solitary throughout the affected
tissue. A rare case of two phosphaturic mesenchymal
tumors has been earlier reported by Nathan et al. In that
published case, single tumor was initially detected in the
tibia, and second tumor was raised two years later in the
maxillary sinus [14]. In a related study, Higley et al. [15]
have showed two unusual cases of TIO characterized by
locally aggressive and multifocal phosphaturic mesen-
chymal tumors. Herein, the authors reported a case of
three phosphaturic mesenchymal tumors along the
tendon sheath in the hallux with no malignancy.
Resecting these tumors resulted in an elevation in serum
level of phosphorus accompanied with complete resolution
of clinical symptoms.
Case presentation
A 39-years old male had a low back pain without any
particular cause, following chest pain, right hip pain, and
bilateral foot pain. One year after these symptoms, he
experienced enlarging elastic soft masses in plantar side
of the right hallux (Fig. 1). He had no remarkable family
history of metabolic bone diseases. He was 172.6 cm tall
and 63.8 kg weight (Body mass index = 21.4 kg/m2) at
the time of his first visit. Laboratory testing of serum
samples revealed normal calcium level of 9.3 mg/dl
(normal range: 8.7-10.3 mg/dl), low phosphorus level
of 1.9 mg/dl (normal range: 2.5-4.5 mg/dl). Alkaline
phosphatase was elevated as noted to be 1245 U/l
(normal range: 115–359 U/l). Serum level of FGF23
Fig. 1 Soft tissue tumor in plantar side of the right hallux
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(215 pg/ml) was at least 4-fold higher normal range
(normal range: 10–50 pg/ml). Urine testing revealed
an elevation in phosphorus concentration coincident a
reduction in tubular phosphate reabsorption. Plain
radiographic images showed cystic radiolucent shadow
in right fourth metatarsal bone, left third and fourth
metatarsal bone, and in right pubis (Fig. 2). Bone
scanning revealed an increased uptake in the bilateral
rib, right pubis, bilateral tarsus, right fourth metatar-
sal bone, left third and fourth metatarsal bone (Fig. 3).
Enhanced MRI showed that three soft tissue tumors
were presented along with right flexor hallucis longus
muscle tendon and one tumor in right first distal
phalanx (Fig. 4). Taken together, this case was diag-
nosed as TIO and these tumors were expected to be
responsible for overproduction of FGF23. To ascertain
our diagnosis, systemic venous sampling for the measure-
ment of FGF23 was conducted. Of note, serum concentra-
tions of FGF23 in right common iliac vein and in right
external iliac vein were higher than other veins (Table 1).
These data indicated that tumors in right hallux detected
with MRI were responsible for the osteomalacia. There-
after, tumors of flexor tendon were resected with the wide
margins. Tumor of distal phalanx found in adhesion
section of flexor tendon was easily excised from sur-
rounding bone. Histological examination of the three
tumors located on flexor tendon showed oval-shaped
mesenchymal cells densely populated in fibrous
background. Moreover, osteoclast-like giant cells and
histiocytes were sparsely found in these tumors asso-
ciated with multifocal haemorrhage and hemosiderin
deposition. Mitotic activity and necrosis were absent
(Fig. 5a, b). On the other hand, the tissue excised
from distal phalanx consisted of hyaline cartilage
and bone tissue showed no tumor (Fig. 5c, d).
The serum level of FGF23 dramatically decreased to
be 47 pg/ml and phosphorus level returned to normal
(3.9 mg/dl), within one hour after the surgery. Serum
concentration of FGF23 became 10 pg/ml one day post-
operation. Moreover, systematic pain was gradually im-
proved, and disappeared two months after surgery.
Discussion
The first case of TIO was reported in 1947 [16], and the
link between phosphaturic mesenchymal tumor and osteo-
malacia was firstly recognized by Prader and colleagues in
1959. Furthermore, the first identification of FGF23 as the
causative factor of TIO was documented in 2001 [17].
FGF23 is a member of the FGF ligand superfamily, pro-
duced by osteogenic cells, osteoblasts and osteocytes, and
functions as regulator of phosphate homeostasis and trans-
port in the kidney. The overproduction of FGF23 by phos-
phaturic mesenchymal tumor results in an elevation of
renal phosphorus wasting and impairment of intestinal
phosphorus absorption, leading to hypophosphatemia and
osteomalacia. FGF23 has negative regulatory effects on
circulating 1,25-dihydroxyl vitamin D by altering cellular
production of 1-alpha hydroxylase and 24-hydroxylase in
kidney [7]. These metabolic disorders impair mineralization
of osteoid matrix in mature bone and cause a defect in the
bone-building process. Therefore, patients with TIO
frequently suffer from multiple fractures and generalized
debilitated status.
In this report, we presented a rare case of osteo-
malacia induced by multiple phosphaturic mesenchy-
mal tumors, diagnosed by MRI and systemic venous
sampling, and confirmed by histopathological exam-
ination. The patient experienced a diffuse bone pain
and multiple fragility fractures due to the disorder in
bone metabolism and the poor mineralization of oste-
oid in mature bone. Laboratory abnormalities that are
often associated with osteomalacia were observed in
this case, including a reduction in serum phosphorus
and an elevation in serum alkaline phosphatase and
FGF23. Three soft tissue tumors and an intraosseous
tumor were found to be located along with the right
hallux. The elevated level of FGF23 in right common
iliac and external iliac veins detected by systemic
Fig. 2 Radiographic observations. a AP radiograph shows cystic radiolucent shadow in right fourth metatarsal bone (arrows) and left third and
fourth metatarsal bone (arrows). b AP radiograph shows cystic radiolucent shadow in right pubis (arrow)
Arai et al. BMC Musculoskeletal Disorders  (2017) 18:79 Page 3 of 6
venous sampling suggested that tumors localized in
the right hallux responsible for the osteomalacia.
Osteomalacia induced by multifocal phosphaturic mesen-
chymal tumors is extremely rare and most of reported TIO
cases are associated with single and small, slow-growing
soft tissue or bone neoplasms tumor [15]. Such attribute
may delay the tumor recognition, localization and
treatment. Imaging modalities including radiographs,
computed tomography scans, MRI, technetium bone
scanning, and positron emission tomography are rou-
tinely used for defining tumor localization. However,
systemic venous sampling that detects the overpro-
duction of FGF23 secreted by phosphaturic mesen-
chymal tumor has been recently recommended for
the definition of tumor localization [9, 10]. In the
current report, localization of phosphaturic mesen-
chymal tumors was defined by systemic venous sam-
pling and MRI, and these tumors were resected with
a wide surgical margin. Complete recovery with no
further complexations was achieved after surgery.
Resected tumors located on right flexor hallux
longus muscle tendon exhibited typical histopatho-
logical features phosphaturic mesenchymal tumors, in-
cluding the numerous number of mesenchymal cells
characterized by spindled to stellate shape and with
small nuclei or indistinct nucleoli. Osteoclast-like
giant cells, histiocyte, haemorrhage, and hemosiderosis
were also present in the lesions. Additional tumor
found in the right distal phalanx had no structure of
mesenchymal tumor consisting of hyaline cartilage
and bone tissue. The presence of osteochondral tissue
in the intraosseous tumor is most likely due to the
overproduction of FGF23 that triggers the differenti-
ation of mesenchymal cells into chondrocyte and
osteocyte, and promotes the proliferation of chondro-
cytes [18, 19].
Fig. 4 Magnetic resonance imaging. Gadolinium-enhanced T2 weighted
magnetic resonance imaging shows three soft tissue tumor presented
along right flexor hallucis longus muscle (arrow) and one tumor in right
first distal phalanx (arrowhead)
Table 1 Systemic venous sampling with measurement of FGF23
Vein Serum FGF23 (pg/ml)
Right internal jugular 164
Left internal jugular 170










Right common iliac 221
Right external iliac 271
Right internal iliac 121
Left common iliac 181
Left external iliac 194
Left internal iliac 180
Fig. 3 Bone scan observation. Image shows an increased uptake in
the bilateral right pubis, bilateral tarsus, right fourth metatarsal bone,
left third and fourth metatarsal bone
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Conclusions
We reported a rare case of TIO caused by multiple
phosphaturic mesenchymal tumors in the hallux. Surgi-
cal resection of tumors resulted in a rapid resolution of
the metabolic disturbance and clinical symptoms. The
osteochondral tissues found in these tumors might be
originated from undifferentiated mesenchymal cells that
may differentiate into chondrocyte and osteocyte by the
overproduction of FGF23.
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